Program
claseprubart
Its studies are mostly in Myasthenia Gravis · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, led by Dianthus Therapeutics.
Furthest: phase 3, since Feb 18, 20254 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dianthus Therapeutics | 44 open or running | phase 3since Feb 18, 2025 | Dec 15, 2023 | Dec 2026phase 2 · NCT06537999 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 15, 2023First study: phase 2 study in Myasthenia GravisFirst studyNCT06282159 · 65 enrolled · United States, Argentina, Canada and more
- Jul 31, 2024Phase 2 study in Multifocal Motor NeuropathyNCT06537999 · 46 enrolled · United States, Canada, China and more
- Feb 18, 2025Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06858579 · 256 planned · United States, Argentina, Australia and more
- May 27, 2026Phase 3 study in Myasthenia GravisNCT07647510 · 195 planned · United States, Georgia, Ukraine
Ahead
- Dec 2026Primary completion: phase 2 study in Multifocal Motor NeuropathyNCT06537999
- Dec 2028Primary completion: phase 3 study in Myasthenia GravisNCT07647510
- Dec 31, 2028Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06858579
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07647510Myasthenia Gravis · United States, Georgia, Ukraine | 3 | Recruiting | Dec 2028 | 195 |
| NCT06858579Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Australia and more | 3 | Recruiting | Dec 31, 2028 | 256 |
| NCT06537999Multifocal Motor Neuropathy · United States, Canada, China and more | 2 | Active, not recruiting | Dec 2026 | 46 |
| NCT06282159Myasthenia Gravis · United States, Argentina, Canada and more | 2 | Active, not recruiting | Jul 28, 2025 | 65 |
How it is read
Names in the registry
- “Claseprubart”, 6 entries
Conditions, from the studies’ own filings
- Myasthenia Gravis, 2 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.